Our research and development activities currently focus on cancer, both hematological malignancies and solid tumors, as well as inflammatory and autoimmune diseases.
Main research areas
We are constantly striving to improve our drug development capabilities, advance our disease expertise to the next level and strengthen our technology suite
Cancer is not a single disease, but includes a large number of heterogeneous indications leading to a wide range of unmet medical needs. Standard treatments for the various forms of cancer include surgery, chemotherapy, radiation therapy and hormone treatment. However, new biological products hold a huge promise for changing treatment paradigms. Drugs such as therapeutic antibodies may allow for highly specific targeting of cancer cells or signaling molecules in order to potentially offer a different safety and efficacy profile.
Our integrated epigenetics platform includes a deep understanding of the biological context in which epigenetic regulators operate, the development of small-molecule product candidates that selectively modulate their activity and the design of clinical development programs supported by novel biomarker strategies.
Immuno-oncology: a new paradigm in the fight against cancer
Immuno-oncology is one of the most exciting areas of research in the biopharmaceutical industry. With the development of therapies that modulate the immune system´s natural ability to fight tumors, researchers are striving to reach major breakthroughs that will overcome the shortcomings of chemotherapy and radiation treatments. Antibody-based immuno-oncologic therapies have shown promise with the potential to provide additional treatment options for a broad range of cancer patients.
Modern immune therapies seek to enhance the immune response against the tumor and block evasion strategies of cancer cells. Multiple steps are needed to generate potent anti-tumor immune responses. MorphoSys has already worked on a range of immune modulator targets and we are leveraging our proprietary Ylanthia® antibody library and other technology platforms to generate antibodies that target specific immune checkpoints.
Inflammatory and autoimmune diseases
Both autoimmune and inflammatory diseases arise through uncharacteristic reactions of the human immune system. In autoimmunity, the patient's immune system is activated against the body's own proteins. In chronic inflammatory diseases, myeloid cells and other leukocytes are constitutively recruited by cytokines and chemokines, leading to tissue damage. Inflammatory disorders include conditions such as rheumatoid arthritis (RA), multiple sclerosis (MS), asthma, chronic obstructive pulmonary disease (COPD), psoriasis and autoimmune kidney diseases.
Inflammatory and autoimmune diseases represent a major challenge for millions of patients.